Cost consequence analysis of adding semaglutide to treatment regimen for patients with Type II diabetes in Saudi Arabia
-
Published:2024-05
Issue:5
Volume:32
Page:102057
-
ISSN:1319-0164
-
Container-title:Saudi Pharmaceutical Journal
-
language:en
-
Short-container-title:Saudi Pharmaceutical Journal
Author:
AlRuthia YazedORCID,
Hani Aburisheh Khaled,
Ata Sondus,
Bin Salleeh Raghad,
Alqudhibi Shahad B.,
Alqudhibi Raghad B.,
Alkraidis Ziad,
Humood Alkhalaf Hala,
Abdullah Almogirah Abdulrahman,
Mujammami Muhammad,
Al Khalifah Reem
Funder
King Saud University
Reference43 articles.
1. A Alabdulkarim, Uranga JG, Bawazir O., 2019. Once-weekly Semaglutide compared to other two GLP1-RAS available in the public healthcare system in the kingdom of saudi arabia: a relative cost of control analysis. ISPOR Europe 2019.
2. Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin;Alexopoulos;Metabolism,2019
3. Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective;Alkhatib;Saudi Pharm J.,2022
4. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
5. Oral Semaglutide versus empagliflozin, sitagliptin and Liraglutide in the UK: long-term cost-effectiveness analyses based on the PIONEER clinical trial programme;Bain;Diabetes Therapy.,2020